- Home
- MYGN vs ADNT Comparison
MYGN vs ADNT Comparison
Compare MYGN & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- ADNT
- Stock Information
- Founded
- MYGN 1991
- ADNT 2016
- Country
- MYGN United States
- ADNT Ireland
- Employees
- MYGN N/A
- ADNT N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ADNT Auto Parts:O.E.M.
- Sector
- MYGN Health Care
- ADNT Consumer Discretionary
- Exchange
- MYGN Nasdaq
- ADNT Nasdaq
- Market Cap
- MYGN 744.7M
- ADNT 1.3B
- IPO Year
- MYGN 1995
- ADNT N/A
- Fundamental
- Price
- MYGN $5.63
- ADNT $22.18
- Analyst Decision
- MYGN Hold
- ADNT Hold
- Analyst Count
- MYGN 15
- ADNT 9
- Target Price
- MYGN $15.14
- ADNT $17.31
- AVG Volume (30 Days)
- MYGN 1.7M
- ADNT 1.5M
- Earning Date
- MYGN 08-05-2025
- ADNT 08-05-2025
- Dividend Yield
- MYGN N/A
- ADNT N/A
- EPS Growth
- MYGN N/A
- ADNT N/A
- EPS
- MYGN N/A
- ADNT N/A
- Revenue
- MYGN $831,300,000.00
- ADNT $14,384,000,000.00
- Revenue This Year
- MYGN N/A
- ADNT N/A
- Revenue Next Year
- MYGN $6.68
- ADNT N/A
- P/E Ratio
- MYGN N/A
- ADNT N/A
- Revenue Growth
- MYGN 7.38
- ADNT N/A
- 52 Week Low
- MYGN $3.81
- ADNT $10.04
- 52 Week High
- MYGN $29.30
- ADNT $26.59
- Technical
- Relative Strength Index (RSI)
- MYGN 60.69
- ADNT 82.50
- Support Level
- MYGN $4.90
- ADNT $19.31
- Resistance Level
- MYGN $5.74
- ADNT $19.91
- Average True Range (ATR)
- MYGN 0.27
- ADNT 0.70
- MACD
- MYGN 0.11
- ADNT 0.17
- Stochastic Oscillator
- MYGN 88.78
- ADNT 93.90
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.8 billion in fiscal 2024 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2024 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.7 billion but will likely be below $14 billion in fiscal 2025 on tariff interruptions and divesting some lower-quality business.